



HAL
open science

Ubiquitination and Deubiquitination – update 2017

Didier Attaix

► **To cite this version:**

Didier Attaix. Ubiquitination and Deubiquitination – update 2017. 10. International Conference on Cachexia, Sarcopenia and Muscle Wasting, Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD). USA., Dec 2017, Rome, Italy. hal-01714759

HAL Id: hal-01714759

<https://hal.science/hal-01714759v1>

Submitted on 5 Jun 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

10th INTERNATIONAL CONFERENCE ON CACHEXIA, SARCOPENIA & MUSCLE WASTING

- > Cachexia in Cancer, Heart Failure, COPD, CKD and Stroke
- > Sarcopenia, Frailty and the Dymobility Syndrome
- > Pathophysiology and Epidemiology of Muscle Wasting
- > Body Composition Assessments
- > Screening, Diagnostic and Management
- > Special Populations
- > Clinical Trial Data

Rapid fire abstracts sessions

Young investigator awards

Plenty of time for discussion

ROME

8-10 DECEMBER 2017



Dear Colleague,

The Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) is pleased to invite you to attend its 10th International Conference on Cachexia, Sarcopenia and Muscle Wasting that will be held on December 8-10, 2017, in Rome, Italy.

As an international and multidisciplinary organization, the SCWD seeks to further research on cachexia, sarcopenia and muscle wasting in order to bring practical solutions to healthcare teams worldwide.

Since the first cachexia conference that took place in Berlin in 2000, over 2000 physicians from over 25 countries have attended our educational sessions.

We expect this SCWD conference in 2017 to be a unique forum for all medical professionals dealing with muscle wasting in their disciplines and we look forward to meeting you in Rome.

We have already more than 180 abstracts and that is very encouraging.

Looking forward to meeting you in Rome.

Yours sincerely,
John E. Morley
Stefan D. Anker

CHAIRMEN:

John E. Morley, St. Louis, MO, USA
Stefan D. Anker, Berlin, Germany

INTERNATIONAL SCIENTIFIC COMMITTEE:

Stefan D. Anker (President) – Berlin, Germany
John E. Morley – St. Louis, USA
William J. Evans – Durham, USA
Akio Inui – Kobe, Japan
Josep M. Argiles – Barcelona, Spain
Filippo Rossi-Fanelli – Rome, Italy
Vickie E. Baracos – Edmonton, Canada
Andrew Coats, Melbourne, Australia and Warwick, UK

Wolfram Doehner – Berlin, Germany
Luigi Ferrucci – Baltimore, USA
David J. Glass – Boston, USA
Aminah Jatoi – Rochester, USA
Kamyar Kalantar-Zadeh – Torrance, USA
Maurizio Muscaritoli - Rome, Italy
Florian Strasser – St. Gallen, Switzerland
Stephan von Haehling – Göttingen, Germany

MORNING

8:00-8:45 Special sessions: pre-registrations only

Statistical Seminar

CHAIRS: Jennifer Le-Rademacher, USA
Jeffrey Crawford, USA

Ken Fearon Career Café – Meet the Mentor

Coordinated by Mitja Lainscak, Slovenia

A 9:00-10:50 Opening SESSION 1

CHAIRS: Stefan Anker, Germany
Maurizio Muscaritoli, Italy
Filippo Rossi-Fanelli, Italy

Welcome by the Chairs

**“Hippocrates” clinical science key note lecture:
Role of mitochondria in age-related muscle impairment**
Luigi Ferrucci, USA

Frailty in 2017

Bruno Vellas, France

Sex differences in cachexia, sarcopenia and wasting disorders

James Carson, USA

Research gaps from the NCI consensus

Joanne Elena, USA

Sarcopenia and cachexia : managing patients in an integrated health care system care: a payer perspective

Bette Caan, USA

10:50-11:20 Coffee break

B 11:20-13:00 Opening SESSION 2

CHAIRS: Josep Argiles, Spain
Andrea Bonetto, USA

**“Prometheus” basic science key note lecture – Sarcopenia revisited:
etiology and consequences**
William Evans, USA

News from proteomic and gene expression data related to aging and cachexia

H. Alexander Ehardt, Ireland

Cause of death in sarcopenia & cachexia

Stefan Anker, Germany

Metabolic modulation by nutrients

Maurizio Muscaritoli, Italy

Precision medicine for cachexia

John Morley, USA

13:15-14:15 Lunch symposium sponsored by Helsinn

AFTERNOON

14:30-16:00

C Clinical Track Translating sarcopenia research across diseases

CHAIR: Zudin Puthuchearu, UK
Linda Denehy, Australia

Skeletal muscle ammonia metabolism in non-hepatological disease

Srinivasan Dasarathy, USA

Kidney dysfunction as a contribution to muscle wasting in chronic illness

Giacomo Garibotto, Italy

Separating inflammation and deconditioning as contributors to muscle wasting in COPD

Paul Greenhaff, UK

Molecular signaling homology across muscle wasting conditions

Dario Coletti, Italy

Sarcopenia in 2017 – what is new?

Francesco Landi, Italy

16:00-17:00 Coffee break & science

16:05-16:55 Poster Viewing Session 1

16:10-16:50 Rapid Fire Abstract Session 1

CHAIRS: Andrea Bonetto, Italy
David Waning, USA

17:00-18:30

E Clinical Track Biological versus numerical aging

CHAIRS: Jann Arends, Germany
Roger Fielding, USA

DNA methylation and the biological clock

Simone Ecker, UK

Frailty scoring: biological aging phenotypes in the critically ill survivors

Zudin Puthuchearu, UK

Relationship between aging and physiological function

Stephen Harridge, UK

Nutritional status and satiety and the interaction with biological ageing

Alessandro Laviano, Italy

Panel discussion

18:30-19:30 Welcome reception & poster viewing

D Basic track Mechanisms of muscle wasting

CHAIRS: Denis Guttridge, USA
Paola Costelli, Italy

Autophagy dysregulation in muscle stem cells during aging

Marco Sandri, Italy

Mechanisms of pathological replacement of skeletal muscle tissue with adipose tissue

Renata Dmitrieva, Russia

Alterations in beta adrenoceptor activity and muscle vs. tissue wasting

Jochen Springer, Germany

ER stress and UPR in skeletal muscle health and disease

Ashok Kumar, USA

Role of JAK/STAT signalling in muscle wasting

Teresa Zimmers, USA

Mitochondrial impairment in skeletal muscle wasting

Antonio Zorzano, Spain

F Basic track Tumor-secreted factors, cytokines and concepts of cachexia development

CHAIRS: Didier Attaix, France
Giovanni Mantovani, Italy

Metabolic regulators of cachexia in cancer

Pankaj Singh, USA

New insights on cancer cachexia

Denis Guttridge, USA

The muscle gp130 receptor's role for cancer-induced anabolic resistance: therapeutic implications for improving cancer survival

James Carson, USA

Mechanisms of muscle atrophy and hypertrophy

David Glass, USA

MYO1 / GDF-15

Samuel Breit, Australia

MORNING

7:45-8:45 Joint session of SCWD & ESPEN

CHAIRS: Stefan Anker, Germany
Maurizio Muscaritoli, Italy

The GLIM and nutrition concept
Tommy Cederholm, Sweden

Is cachexia truly malnutrition?
John Morley, USA

Panel discussion

Stefan Anker, Josep Argilés, Vickie Baracos, Tommy Cederholm, Andrew Coats, Bill Evans, John Morley, Maurizio Muscaritoli

8:00-8:45 Special sessions: pre-registrations only

Statistical Seminar

CHAIRS: Jennifer Le-Rademacher, USA
Jeffrey Crawford, USA

Ken Fearon Career Café – Meet the Mentor

Coordinated by Mitja Lainscak, Slovenia

9:00-10:30

G Recent developments and updates on CT imaging for body composition analysis

CHAIRS: Andrew Coats, UK
Joanne Elena, USA

Methodological standards of CT imaging and its use as endpoint in clinical trials
Vickie Baracos, Canada

Clinical practice of anti-cancer treatment dose adaption by muscle mass data
Florian Strasser, Switzerland

CT based muscle radiodensity as prognostic marker
Sami Antoun, France

CT based assessment of muscle mass in clinical trials: the reality check and industry view
Jeffrey Crawford, USA

Advances in automatic CT image segmentation - application for body composition analysis?
Karteek Popuri, Canada

CT imaging in phase 2/3 trials - what the regulators expect to see?

10:30-11:30 Coffee break & science

10:35-11:25 Poster Viewing Session 2

10:40-11:20 Rapid Fire Abstract Session 2

CHAIRS: Egidio Del Fabbro, USA and Paul Gregorevic, Australia

11:30-13:00

J Muscle loss in liver diseases

CHAIRS: Srinivasan Dasarathy, USA
Pankaj Singh, USA

Epidemiology and clinical significance of sarcopenia in liver cirrhosis
Mathias Plauth, Germany

Significance of sarcopenia and sarcopenic obesity in fatty liver
Manuela Merli, Italy

Molecular mechanisms of sarcopenia in liver cirrhosis
Michela Giusto, Italy

Role of MiF in muscle wasting
Steven Olde Damink, The Netherlands

Treatment approaches for muscle wasting in liver cirrhosis
Srinivasan Dasarathy, USA

K Cachexia: not just muscle

CHAIRS: James Carson, USA
Jochen Springer, Germany

The bone-muscle cross-talk
David Waning, USA

Adipogenic drive in cancer-induced muscle wasting
Paola Costelli, Italy

Energy metabolism, mitochondria and cachexia in COPD
Anemie Schols, The Netherlands

Metabolic regulation of fat in cancer cachexia
Stefan Herzig, Germany

Protecting fat to gain muscle – a possible new therapeutic concept?
Jeffrey Crawford, USA

L Nutritional approaches to combat sarcopenia & cachexia

CHAIR: Nicolaas Deutz, USA
Alessandro Laviano, Italy

Malnutrition and cachexia in cancer patients at first medical oncology visit
Maurizio Muscaritoli, Italy

Micronutrients in sarcopenia and age-related physical decline
Jerome Feige, Switzerland

Interaction exercise and nutrition in sarcopenia
Roger Fielding, USA

The efficacy of a novel oral nutrition supplement in tackling sarcopenia in the elderly
Pol Grootswagers, The Netherlands

Proteins to treat sarcopenia
Jürgen Bauer, Germany

Trial experience in wasting disorders using nutritional approaches
Jann Arends, Germany

13:15-14:15 Lunch symposium sponsored by Stealth Biotheapeutics

AFTERNOON

14:30-16:00

M Models of cachexia

CHAIRS: Stefan Herzig, Germany
Jochen Springer, Germany

Human xenografts as a suitable model for studying cancer cachexia
Andrew Judge, USA

Modeling cachexia: the impact of anti-neoplastic therapy
Andrea Bonetto, USA

Experimental models for aging and sarcopenia
Sue-Joan Chang, Taiwan

New experimental model of cancer cachexia & kidney disease
Daniel Marks, USA

Large animal models of human cachexia: update 2017
Lisa Freeman, USA

N Cachexia at its worst

CHAIRS: Vickie Baracos, Canada
Stephan von Haehling, Germany

Diagnostic criteria for the classification of cancer-associated weight loss
Egidio Del Fabbro, USA

Wasting of muscle involved in swallowing and mastication
Florian Strasser, Switzerland

Diagnosis and management of oropharyngeal dysphagia
Anne Letsch, Germany

Treating shortness of breath in advanced cancer cachexia – the muscle hypothesis
Andrew Coats, UK

Palliative care and anabolic therapies
Aminah Jatoi, USA

O Targeting skeletal muscle – from research to clinical development

CHAIRS: Ashok Kumar, USA
Antonio Zorzano, Spain

Biopsies of skeletal muscle – a source of new understanding
Volker Adams, Germany

Muscle satellite cells
Camila Almeida, Brazil

Diabetes and muscle
Leocadio Rodríguez Mañas, Spain

Gene therapy approaches to treat cancer cachexia
Paul Gregorevic, Australia

Cachexia & sarcopenia – how to develop and get approved drugs there
Giuseppe Rosano, UK

16:00-17:00 Coffee break & science

16:05-16:55 Poster Viewing Session 3

16:10-16:50 Rapid Fire Abstract Session 3

CHAIRS: Josep Argiles, Spain and Aminah Jatoi, USA

17:00-18:30

P Rehabilitation in advanced elderly cancer patients with cachexia

CHAIRS: Paolo Bossi, Italy
Florian Strasser, Switzerland

Muscle of the elderly and physical activity: balancing over- and undertreatment
Francesco Landi, Italy

Exercise training as an effective tool to improve cancer-induced muscle wasting
Fabio Penna, Italy

What can cancer cachexia rehabilitation trials learn from critical care rehabilitation?
Linda Denehy, Australia

Rehabilitative-geriatric interventions in elderly advanced cancer patients: who will respond?
Pierre Soubeyran, France

Perspectives of health care professionals on cancer cachexia: results from three global surveys
Alessio Molfino, Italy

Q Potential treatments for muscle wasting and cachexia

CHAIR: Volker Adams, Germany
Marco Sandri, Italy

MEK inhibitors as potential tools to improve cancer-induced muscle wasting
Erin Talbert, USA

MAGIC-F1 modulations to improve myogenesis
Maurilio Sampaolesi, Italy

New drug targets from a neglected hormone? Unacylated Ghrelin and the regulation of muscle mass and muscle repair
Andrea Graziani, Italy

Drugs modifying catabolic/anabolic balance: ACE inhibitors + beta-blockers
Mitja Lainscak, Slovenia

What else is new?
William Evans, USA

R Muscle wasting and cachexia in chronic illnesses – update 2017

CHAIRS: Anнемie Schols, The Netherlands
Giacomo Garibotto, Italy

COPD
Stefan Andreas, Germany

Chronic heart failure
Stephan von Haehling, Germany

Chronic kidney disease failure
Robert Mak, USA

Stroke
Wolfram Doehner, Germany

Cancer
Jeffrey Crawford, USA

6:00-7:00 **JCSM board**

7:15-8:15 **Session of the Journal of Cachexia, Sarcopenia and Muscle (JCSM)/SPRINTT**

8:30-9:45

S Imaging methods for assessing muscle mass
CHAIRS: Vickie Baracos, Canada
 Steven Heymsfield, USA

Body impedance
 M. Christina Gonzalez, Brazil

Cross-sectional: CT or MRI
 Vickie Baracos, Canada

Quadriceps contractile volume by MRI
 Thomas Maden-Wilkinson, UK

Ultra-sound methods
 Thiago Gonzalez Barbosa-Silva, Brazil

Panel discussion

T Frailty & sarcopenia – update 2017
CHAIRS: Jürgen Bauer, Germany
 John Morley, USA

The physical frailty phenotype
 John Morley, USA

Treatment trials for frailty
 Eva Topinkova, Czech Republic

Validating SARC-F
 Jean Woo, Hong Kong

The role of T2DM in the development of sarcopenia and frailty
 Theodore Malmstrom, USA

Treating sarcopenia
 Tommy Cederholm, Sweden

9:45-10:45 **Coffee break & science**

9:50-10:40 **Poster Viewing Session 4**

10:45-12:10

U Clinical trials in progress
CHAIRS: Aminah Jatoi, USA
 Andrew Coats, UK

Re-testing fish oil for cachexia
 Maria Öhlander, Norway

Pluripotent cells to treat muscle wasting after orthopedic surgery
 Tobias Winkler, Germany

Peptamen for weight loss
 Andrew Hendifar, USA

Cannabis for cancer-associated weight loss
 Moran Grinberg, Israel

Rare disease drug development considerations
 Anthony Aiudi, USA

V Intensive care unit myopathy and beyond: Molecular signals and clinical observations
CHAIRS: William Evans, USA
 Samuel Breit, Australia

Introduction and historical data: nutritional intervention strategies
 Nicolaas Deutz, USA

Inflammation as a trigger for rapid loss of muscle: pre-clinical and clinical data
 Paul Greenhaff, UK

Molecular signals in skeletal muscle from ICU patients: the role of GDF-15
 Mark Griffiths, UK

GFRAL, the receptor for GDF15
 Shamina Rangwala (USA)

Clinical experience: treating muscle wasting in the ICU
 Tobias Wollersheim, Germany

12:15-13:15 **Lunchtime symposium sponsored by Fresenius-Kabi**

13:20-14:45

W Late breaking clinical trials & trial updates
CHAIRS: Andrew Coats, UK
 Stefan Anker, Germany

X Anorexia of disease, fasting metabolism and clinical outcome
CHAIR: Filippo Rossi-Fanelli, Italy
 Florian Strasser, Switzerland

Targeting the adipose tissue in cancer cachexia
 Josep Argiles, Spain

Lessons from fasting metabolism: is there any benefit of anorexia during disease?
 Alessandro Laviano, Italy

Gut-brain axis: role of microbiota in anorexia of disease
 Serguei Fetissov, France

Filling the caloric gap during disease: does it ameliorate clinical outcomes?
 Marian de van der Schueren, The Netherlands

Gastrointestinal hormones: a suitable target to treat anorexia of disease?
 Jessie Elliott, Ireland

Y 14:45-15:45 Highlights of the congress

CHAIRS: Stefan Anker, Germany - Maurizio Muscaritoli, Italy - Annemie Schols, The Netherlands

Basic science & pathophysiology
 Annemie Schols, The Netherlands

Body composition
 Steven Heymsfield, USA

Sarcopenia
 Stephan von Haehling, Germany

Nutrition treatment
 Roger Fielding, USA

Cachexia of chronic illness and its therapy
 Andrew Coats, UK

Awards Ceremony

Best Poster Award • Young Investigators Award • Trainee Poster Award

EDUCATIONAL OBJECTIVES:

Following this activity, the audience will be able to:

1. Review the latest information about the pathophysiology of muscle wasting and its epidemiology.
2. Screen for and diagnose cachexia, sarcopenia, frailty and dysmobility resulting from the following diseases or chronic conditions: cancer, cardiovascular disease, COPD, CKD, dementia/Alzheimer's disease, diabetes, infectious diseases, stroke and aging.
3. Develop appropriate management programs for patients across the continuum of care.

TARGET AUDIENCE:

Internists, oncologists, cardiologists, gerontologists, palliative care specialists, primary care physicians and nurses.

Organization

MEDED GLOBAL SOLUTIONS

27, rue Raffet, 75016 Paris, France

Tel: +33 (0)1 44 01 51 81

Fax: +33 (0)1 44 01 51 80

E-mail: scwd@mededgs.com

www.cachexia.org



Online registration:

www.cachexia.org

DATES

Friday, December 8, 2017
to Sunday, December 10, 2017

ABSTRACTS

All abstracts will be published
in the Journal of Cachexia,
Sarcopenia and Muscle (JCSM).

VENUE

**Sheraton Roma Hotel
& Conference Center**
Viale Del Pattinaggio, 100
Rome, 00144, Italy

> Official language: English